Townsend & Associates’s AbbVie ABBV Stock Holding History

Townsend & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Sell	10,960 -160	-1%	-$34.4K	0.24%	51
2026 Q1	$2.23M	Sell	11,120 -47	-0.4%	-$10.4K	0.19%	55
2025 Q4	$2.42M	Sell	11,167 -446	-4%	-$102K	0.22%	53
2025 Q3	$2.67M	Sell	11,613 -82	-0.7%	-$16.7K	0.25%	50
2025 Q2	$2.23M	Buy	+11,695	New	+$2.17M	0.22%	50
2022 Q2	–	Sell	-13,747	Closed	-$2.4M	–	79
2022 Q1	$2.4M	Buy	13,747 +1,074	+8%	+$156K	1.11%	29
2021 Q4	$1.72M	Buy	+12,673	New	+$1.5M	0.94%	45
2018 Q4	–	Sell	-12,147	Closed	-$1.15M	–	72
2018 Q3	$1.15M	Buy	12,147 +2,482	+26%	+$235K	1.14%	34
2018 Q2	$895K	Buy	9,665 +665	+7%	+$64.9K	1%	37
2018 Q1	$852K	Buy	9,000 +891	+11%	+$97.9K	0.68%	33
2017 Q4	$784K	Buy	+8,109	New	+$764K	0.67%	40

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Townsend & Associates's ABBV Position: Q2 2026 in Review

Townsend & Associates reduced its AbbVie (ABBV) stake by 1.4% in Q2 2026, selling an estimated $34.4K and leaving 10,960 shares worth $2.78M. The position accounts for 0.24% of the portfolio, ranked #51.

Townsend & Associates first reported a position in ABBV in Q4 2017 and has held it in 11 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Townsend & Associates held 10,960 shares of AbbVie worth $2.78M as of Q2 2026.
Townsend & Associates sold 160 AbbVie shares in Q2 2026, an estimated $34.4K.
AbbVie made up 0.24% of Townsend & Associates's portfolio in Q2 2026, its #51 holding.
Townsend & Associates first reported a position in AbbVie in Q4 2017 and has held it in 11 quarters since.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Townsend & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.